🔗 Share this article

An underground economy for unapproved slimming drugs is being driven by social media fitness personalities and vendors on messaging platforms, according to recent findings.

Investigational Drug Gaining Traction Via Social Media

The experimental drug, which is still in clinical trials, is being promoted by online personalities for its supposed fat-burning effects. Followers are encouraged to message these accounts directly for supplier links, while also receiving discount codes.

Active Trade on Messaging Platforms

Separately, a robust market exists on Telegram, where groups with numerous of participants share comparison images, injection guides and claims of rapid UK delivery. Sellers promote the substance there before redirecting buyers to WhatsApp for transactions.

Learning About The Experimental Drug

This medication is an investigational injection developed by US drugmaker Eli Lilly. The treatment targets three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon. Preliminary studies suggest it could help individuals reduce up to 25% of their total weight. Nicknamed the “triple G”, the drug is being promoted online as the successor to Ozempic.

Medical Experts Voice Worries

However, doctors and pharmacists have warned that the sale of what is still an unapproved drug in the UK is worrisome and could lead to individuals administering products of unknown origin.

Several professionals stated the popularity for the experimental drug could be connected to the increasing price of licensed slimming products such as Mounjaro.

Regulatory Position and Implementation

Marketing the unapproved drug on social media or Telegram is illegal in the United Kingdom, as it is an unlicensed medication that must not be promoted or distributed for personal consumption under the British medical regulations.

Several content creators attempt to circumvent the rules by calling to the substance as a “research chemical” or citing it as “not for human consumption”. The substance is not a restricted drug, but advertising and supply can still breach pharmaceutical, advertising, and customer regulations, potentially leading to penalties, legal action or prison.

Platform Reaction and Content Removal

Based on the social media company, the platform has removed problematic content and prohibited related keywords and query recommendations. The organization stated it was dedicated to maintaining the platform secure and investing in strengthening enforcement strategies.

Digital Trading Operations

Investigations also found groups with up to 9,000 members selling retatrutide using Telegram's integrated search feature, which functions like a online catalog. Typing “retatrutide” immediately displays groups with thousands of members, filled with images of weight loss, glowing reviews and step-by-step guides for preparing or injecting at home.

Within moments of entering one group, a vendor shared contact information, where most transactions take place. The vendor provided an guidebook and guaranteed shipping within two days. When asked whether the substance was genuine, one vendor responded: “You can’t be sure.” Another shared a image of a alleged testing documentation. Not one inquired about weight, medical conditions or previous experience.

Product Details and Costs

Inside these communities, posts show dark colored parcels with postal service stickers, stating to include fresh supplies. One message read: “It took eight of us to load them this morning.”

Buyers can choose between powder vials, prepared at home with sterile water, or ready-to-use pens usually priced at £160 for 20mg. When questioned how much time a injector should last, sellers give conflicting answers ranging from a few weeks to “depends on your body”.

Service Oversight and Security Measures

A representative for the messaging service said it actively monitored dangerous content on its platform including material that promoted the “misuse of controlled medications”. The company added that it removed “millions of pieces of harmful content each day”.

Healthcare Professional Cautions

“Individuals are injecting materials they cannot confirm. Even if the research behind retatrutide is valid, these online versions may not include what they claim,” said a pharmacy expert, the head of pharmaceutical services at Chemist4U.

A medical professional of an online medical service connected the increase in interest to recent cost increases for authorized slimming medications such as Mounjaro. “With costs rising, patients are turning to social media. But counterfeit treatments are highly dangerous. You cannot know what’s contained or whether the environment they were made in was clean,” she explained.

Her team has already seen individuals injured by self-injection from unverified sources. “We understand the frustration, but purchasing from messaging apps or WhatsApp is gambling with your health,” stated the doctor. “These materials could be contaminated or improperly measured.”

Manufacturer Statement

A spokesperson from the pharmaceutical company said retatrutide was in third stage clinical trials and had not been reviewed or authorized by any government authority globally. “Consequently at this point no one can market [it] for human use,” they said, adding that any product “falsely representing itself as a Lilly investigational product not yet authorized … may subject users to potentially significant health risks”.